Article Text

Download PDFPDF
UK survey of Pneumocystis jirovecii Pneumonia (PJP) prophylaxis use in paediatric oncology patients
  1. Rebecca Proudfoot1,
  2. Rachel Cox2,
  3. Bob Phillips3,
  4. Sophie Wilne4
  1. 1 Department of Paediatric oncology, John Radcliffe Hospital, Oxford, UK
  2. 2 Paediatric Oncology Department, Bristol Children's Hospital, Bristol, UK
  3. 3 Centre for Reviews and Dissemination, University of York, York, UK
  4. 4 Paediatric Oncology Department, University Hospitals Nottingham NHS Trust, Queen's Medical Centre, Nottingham, UK
  1. Correspondence to Dr Rebecca Proudfoot, Department of Paediatric Oncology, John Radcliffe Hospital, Headley Way, Oxford OX3 9DU, UK; Rebecca.proudfoot{at}

Statistics from

Pneumocystis jirovecii, previously known as Pneumocystis cariniii , is an opportunistic parasite that causes P. jirovecii pneumonia (PJP) in immunocompromised hosts. Most immunocompetent children acquire asymptomatic infection with P. jirovecii by the age of 4 years,1 while symptomatic disease occurs almost exclusively in severely immunocompromised hosts.

Pneumocystis has been recognised as a cause of pneumonia since the 1940s when epidemics of ‘plasma cell pneumonia’ were diagnosed in malnourished and premature infants in care homes in Eastern Europe.2 In the 1960s, as immunosuppressive therapy for malignancy …

View Full Text

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.